Immix Biopharma, Inc.
IMMXHealthcareNASDAQBiotechnology · Last scanned Jul 18, 2026
Headquartered within the healthcare sector, Immix Biopharma, Inc. focuses on Biotechnology services and products. Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the. Valued at $729.7M, IMMX is a small-cap name in its sector. The company' lead product is NXC-201 for relapsed/refractory AL Amyloidos.
Market Cap
$729.7M
Beta
0.09
P/E (TTM)
—
P/E (Fwd)
-13.82
EPS (TTM)
$-0.94
EPS (Fwd)
$-0.74
ROE
-74.5%
ROA
-39.0%
Cash
$90.6M
Total Debt
$1.0M
Free CF
-$20.3M
52W Change
245.1%
Annual Financials
Cash vs Debt
The balance sheet looks solid with $90.6M in cash comfortably exceeding the $1.0M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. The company is burning cash, with free cash flow at -$20.3M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -74.5%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
The relatively low beta of 0.09 suggests IMMX is a less volatile holding compared to the broader index. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing IMMX.